ResQ Pharma

ResQ Pharma is a research and development company focused on commercializing its primary program, LipidRescue Therapy (LRT), which is an off-label treatment currently used for various non-opiate drug overdoses and poisonings, including local anesthetics like Lidocaine and Bupivacaine, as well as benzodiazepines and psychotherapeutics such as antidepressants. The company aims to repurpose an FDA and EMA-approved lipid emulsion, originally a nutritional supplement, with plans to file for market approval in the EU and USA by the first quarter of 2017. Applications for Orphan Drug Designation are already pending with the FDA and EMA. Despite its global use since 2010, the lipid emulsion has not received regulatory approval as a treatment for overdoses and poisonings, limiting its marketability and awareness among healthcare professionals. In 2015, approximately 47,000 people died from drug overdoses and poisonings, with an estimated 40% potentially treatable with LRT. The company's last investment was a Venture Round investment of $205.50K on 16 June 2022. The investor information is not available. ResQ Pharma operates in the Biopharma and Biotechnology industries. ResQ Pharma's efforts to bring LRT to market and address the unmet need for overdose and poisoning treatments present an opportunity for addressing a significant public health issue while potentially capturing market share.